Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

IMP-288

Known as: IMP 288, IMP288 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Purpose The aim of this study was to compare the performances pretargeted immunoPET 68Ga-PETimaging (68Ga-pPET) with anti carcino… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2015
2015
OBJECTIVES A phase I pretargeted radioimmunotherapy trial (EudractCT 200800603096) was designed in patients with metastatic lung… Expand
Is this relevant?
2014
2014
PurposePretargeting with bispecific antibodies and radiolabeled hapten-peptides could be used to specifically target tumors with… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
UNLABELLED TROP-2 is a pancarcinoma marker that is expressed at high levels in many epithelial cancers, including prostate cancer… Expand
Is this relevant?
2014
2014
Abstract TROP-2 is a pancarcinoma marker that is expressed at high levels in many epithelial cancers, including prostate cancer… Expand
Is this relevant?
2013
2013
PurposeTF12 is a trivalent bispecific antibody that consists of two anti-TROP-2 Fab fragments and one anti-histamine-succinyl… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
The prospects for using pretargeted immuno-SPECT to monitor the response to pretargeted radioimmunotherapy were examined. In this… Expand
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
2011
2011
Bispecific antibody pretargeting is highly sensitive and specific for cancer detection by PET. In this study, the preparation of… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 4
  • figure 3
Is this relevant?
2010
2010
Pretargeted radioimmunotherapy (PRIT) with bispecific antibodies in combination with a radiolabeled peptide reduces the radiation… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 5
  • figure 6
Is this relevant?
2010
2010
Objective: Radiolabeled antibodies were being developed commercially for the detection of several cancer types. However, imaging… Expand
Is this relevant?